Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series

Jillian F Wise; Sigve Nakken; Chloé B Steen; Daniel Vodák; Gunhild Trøen; Bjarne Johannessen; Ole Christian Lingjærde; Vera Hilden; Yngvild Nuvin Blaker; Baoyan Bai; Lars Birger Aasheim; Annika Pasanen; Susanne Lorenz; Anita Sveen; Ragnhild A Lothe; Ola Myklebost; Sirpa Leppä; Leonardo A Meza-Zepeda; Klaus Beiske; Michael S Lawrence; Eivind Hovig; June Helen Myklebust; Erlend B Smeland; Harald Holte

doi:10.1182/bloodadvances.2019001325

Mutational dynamics and immune evasion in diffuse large B-cell lymphoma explored in a relapse-enriched patient series

Blood Adv. 2020 May 12;4(9):1859-1866. doi: 10.1182/bloodadvances.2019001325.

Authors

Jillian F Wise^{1

2

3

4

5

6}, Sigve Nakken^{2

7

8

9}, Chloé B Steen^{1

10}, Daniel Vodák^{2

7

8}, Gunhild Trøen¹¹, Bjarne Johannessen^{8

12}, Ole Christian Lingjærde¹⁰, Vera Hilden^{1

3}, Yngvild Nuvin Blaker^{1

3

8}, Baoyan Bai^{1

3}, Lars Birger Aasheim^{2

7}, Annika Pasanen^{13

14}, Susanne Lorenz^{2

7

15}, Anita Sveen^{8

12}, Ragnhild A Lothe^{2

8

12}, Ola Myklebost^{2

7

16}, Sirpa Leppä^{13

14}, Leonardo A Meza-Zepeda^{2

7

15}, Klaus Beiske^{8

11}, Michael S Lawrence^{4

5

6}, Eivind Hovig^{2

7

10}, June Helen Myklebust^{1

3}, Erlend B Smeland^{1

2

3}, Harald Holte^{2

3

17}

Affiliations

¹ Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
² Norwegian Cancer Genomics Consortium, Oslo, Norway.
³ K. G. Jebsen Centre for B-cell Malignancies, Faculty of Medicine, University of Oslo, Oslo, Norway.
⁴ Massachusetts General Hospital Cancer Center, Boston, MA.
⁵ Department of Pathology, Harvard Medical School, Charlestown, MA.
⁶ Broad Institute of Harvard and MIT, Cambridge, MA.
⁷ Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
⁸ Institute of Clinical Medicine, Faculty of Medicine.
⁹ Centre for Cancer Cell Reprogramming, Institute of Clinical Medicine, Faculty of Medicine, and.
¹⁰ Department of Informatics, University of Oslo, Oslo, Norway.
¹¹ Department of Pathology and.
¹² Department of Molecular Oncology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
¹³ Department of Oncology, Helsinki University Hospital Cancer Center, Helsinki, Finland.
¹⁴ Research Program Unit, Faculty of Medicine, University of Helsinki, Helsinki, Finland.
¹⁵ Genomics Core Facility, Department of Core Facilities, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
¹⁶ Department for Clinical Science, University of Bergen, Bergen, Norway; and.
¹⁷ Department of Oncology, Oslo University Hospital, Oslo, Norway.

Abstract

Diagnostic and relapse diffuse large B-cell lymphoma (DLBCL) biopsies reveal increased mutational burden/loss of heterozygosity in HLA-A.
Serially sampled tumor biopsies provide insight into therapeutic targets and evolutionary divergence in relapsed/refractory DLBCL.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Humans
Immune Evasion*
Lymphoma, Large B-Cell, Diffuse* / genetics
Mutation
Neoplasm Recurrence, Local